SiNtx Technologies Inc (SINT)

[boston745]

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they’re getting closer

Drugmakers have poured billions of dollars into developing ADCs. The medicines are designed to deliver potent chemotherapy directly to cancer cells while sparing surrounding healthy cells. That’s unlike traditional chemotherapy, which can affect both types of cells.

A range of drugmakers want in on the hype, and for good reason. ADCs could account for $31 billion of the $375 billion worldwide cancer market in 2028, according to estimates from the drug market research firm Evaluate.

ADCs still pose major challenges. Among them, some treatments can release the toxic chemotherapy “payload” into the bloodstream too soon, affecting healthy cells and causing a range of side effects. Some health experts say drugmakers also need to identify the right cancer-causing proteins to target and new payloads for these drugs.

Another method in development is microspheres for longterm delivery of ADCs.

Among these, microspheres have been studied extensively regarding their excellent tolerance at the injection site, controllable loading and release of drugs, and good material safety. Subcutaneous injection is favored by most patients because it can be quickly self-administered. Subcutaneous injection of microspheres is expected to become the focus of developing long-lasting antibody drug strategies in the near future.

SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment

announces the signing of a Joint Development Agreement (JDA) with NED Medical Inc., an innovative developer of oncology embolization therapy technologies. This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.

At the time of the press release, the micospheres had already been developed for Ned and development had begun before Dr Luke Higgins, who I think is the son of Zimmer Biomet's Arthur Higgins, joined Ned Medicals scientific board,

Luke Higgins, MD, Ph.D., an MIT/Harvard/Stanford-trained Interventional Radiologist with a prior research focus on nanoparticle-mediated cancer-specific DNA delivery targeting liver cancer cells.

Sintx and Ned have been very quiet on development front since announcing this JDA.

Quote Sources:
https://www.cnbc.com/2025/06/17/adc-cancer-drugs-pfizer-astrazeneca-merck-bet-on-chemo-replacement.html
https://link.springer.com/article/10.1007/s13318-024-00891-7
https://finance.yahoo.com/news/sintx-technologies-ned-medical-partner-110000929.html
https://nedmedical.com/ned-medical-launches-world-class-scientific-advisory-board/